Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy
Global and Regional Health Technology Assessment · 01.05.2026 · 13 (1) · 109-117
DOI: 10.33393/grhta.2026.3642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 01.05.2026. Verfasst von Chiara Bini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Ve…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Human immunoglobulins are the standard of care for patients with immunodeficiencies and represent a first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to evaluate costs associated with facilitated subcutaneous (fSCIG), conventional subcutaneous (cSCIG), and intravenous (IVIG) administration of immunoglobulin in patients with primary or secondary immunodeficiency (PID and SID, respectively) and in patients with CIDP in Italy.
Methods
A cost-minimization analysis from a societal perspective was developed, considering a one-year follow-up. Direct costs included acquisition and administration costs, while indirect costs were evaluated considering productivity loss due to in-hospital IVIG using a Human Capital Approach. The posology considered for immunodeficiency disorders and CIDP was obtained from observational studies and clinical trials, respectively. Subcutaneous and intravenous administration costs were obtained from published literature. Scenario analyses were conducted to test the key assumptions of the model.
Results
This study indicates a potential reduction of annual societal expenditure in Italy of approximately €2,145 and €1,605 with fSCIG treatment in PID patients compared to cSCIG and IVIG, respectively. In SID patients, fSCIG would result in a reduction of societal expenditure of approximately €2,145 and €2,071 compared to cSCIG and IVIG. For CIDP patients, fSCIG treatment would result in a reduction of societal expenditure of €8,060 and €15,873 compared to cSCIG and IVIG, respectively.
Conclusion
The use of fSCIG for patients with PIDs, SIDs or CIDP could lead to a reduction in the direct and indirectcosts associated with the treatment of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", Rome - Italy.
- Patient Value & Access Department, Takeda Italia S.p.A., Rome - Italy.
- Medical & Regulatory Department, Takeda Italia S.p.A., Rome - Italy.
ORCID-Profile: Chiara Bini, Carmela Papa
Zitieren
APA
Bini, C., Scortichini, M., Ripoli, S., Fioravanti, L., Papa, C., & Sciattella, P. (2026). Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy. Global and Regional Health Technology Assessment, 13(1), 109-117. https://doi.org/10.33393/grhta.2026.3642
Vancouver
Bini C, Scortichini M, Ripoli S, Fioravanti L, Papa C, Sciattella P. Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy. Global and Regional Health Technology Assessment. 2026;13(1):109-117. doi:10.33393/grhta.2026.3642
BibTeX
@article{Bini2026,
author = {Bini, Chiara and Scortichini, Matteo and Ripoli, Silvia and Fioravanti, Laura and Papa, Carmela and Sciattella, Paolo},
title = {Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {109--117},
doi = {10.33393/grhta.2026.3642}
}
EUVIMED